Direct Selective Laser Trabeculoplasty (DSLT) for Reducing Eye Pressure in Non-Caucasian Patients With Open Angle Glaucoma
Condition(s) studied
Investigational drug(s) / intervention(s)
Direct Selective Laser Trabeculoplasty: DSLT using the Belkin Vision Eagle Device
Study summary
The goal of this clinical trial is to to evaluate how well Direct Selective Laser Trabeculoplasty (DSLT) lowers eye pressure in eyes of adult, non-Caucasian participants with primary open angle glaucoma. The main question it aims to answer is:
What is the washed out eye pressure (eye pressure when not on any glaucoma medications) of participants 6 months after the Direct Selective Laser Trabeculoplasty (DSLT) procedure compared to the washed out eye pressure of participants prior to the DSLT procedure.
Participants will:
Undergo the DSLT procedure in one or both eyes and visit the clinic 1 month, 3 months, and 6 months after the procedure to have their vision and eye pressure measured.
Eligibility
Primary outcome measure(s)
- IOP reduction at 6 months washed out post-DSLT compared with washed out baseline IOP. — 6 Months post-DSLT
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Select Eye Care | Elkridge | Maryland | Recruiting |
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07147647 on ClinicalTrials.gov ↗ ← All trials in the USA